CryoStor® Cell Preservation Selected For Phase III Clinical Trials of C-Cure® Cell Therapy for Congestive Heart Failure

Cardio3 BioSciences, a leader in engineered cell therapy with clinical programs initially targeting indications in cardiovascular disease and oncology, has embedded the Company’s clinical grade CryoStor cryopreservation freeze media in its ongoing Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) phase III clinical trial in Europe and Israel and the pending CHART-2 phase III clinical trial to be conducted in the United States.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news